Quanterix Corp sets out growth plans, shares trade on Nasdaq
25.06.2026 - 14:19:30 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 14:19.
Quanterix Corp (US74876Y1001) develops ultra-sensitive digital biomarker assays and trades on the Nasdaq in New York, putting it in the global health-tech spotlight. The company is building out its business on the back of the Simoa technology platform, as its investor materials show. Quanterix investor news overview
Quanterix business built around Simoa
Quanterix Corp focuses on high-precision measurement of proteins and biomarkers in blood and other fluids using its proprietary Single Molecule Array, or Simoa, platform, which the company highlights as its core technology. Its operations target pharmaceutical and academic research customers as well as diagnostic partners. Company description on the Quanterix website
The company positions Simoa to support neurology-focused biomarker programs, including assays for amyloid beta, tau and neurofilament light, with applications in Alzheimer research and other neurodegenerative diseases. This focus places Quanterix alongside listed peers such as Bio-Techne and Meso Scale Diagnostics in the broader life-science tools sector.
Strategic focus and operational setup
Quanterix operates primarily out of the United States and reports through a model that combines instrument placements with recurring consumables and services revenue, a setup common among life-science tools providers. Customers use Simoa instruments in drug development and clinical research programs, which can run for several years. Quanterix corporate presentation
The company also emphasizes collaborations with large pharmaceutical companies and research institutions to expand the assay menu and validate biomarkers in large cohorts. This collaborative approach is designed to tie instrument placements to long-term assay demand, stabilizing revenue streams in a competitive environment.
Further coverage and documents on Quanterix Corp
Investors can follow all articles on Quanterix Corp and access original investor documents for a fuller picture of the stock.
How Quanterix generates revenue
Quanterix generates revenue primarily from the sale of Simoa instruments, consumable assay kits and related services, including testing performed in its own laboratories. This combination creates an installed base of instruments that drives recurring consumables revenue.
Where Quanterix trades today
Quanterix Corp shares trade on Nasdaq in the United States; current price and trading data are available directly via the Nasdaq and common quote services.
Quanterix Corp at a glance
- Company: Quanterix Corp Inc.
- ISIN: US74876Y1001
- WKN: A2JH9P
- Ticker: QTRX
- Trading venue: Nasdaq
- Price (as of 2026-06-25, 12:10): [value] USD
- Market cap: [value] USD (as of 2026-06-25)
- Sector / industry: Health Care - Life Science Tools & Services
- Index membership: not part of a major headline index such as S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
